Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

8-2019

Classification criteria for autoinflammatory recurrent fevers.
Marco Gattorno
Michael Hofer
Silvia Federici
Federica Vanoni
Francesca Bovis

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub
Part of the Pediatrics Commons

Authors
Marco Gattorno, Michael Hofer, Silvia Federici, Federica Vanoni, Francesca Bovis, Ivona Aksentijevich,
Jordi Anton, Juan Ignacio Arostegui, Karyl Barron, Eldad Ben-Cherit, Paul A Brogan, Luca Cantarini,
Isabella Ceccherini, Fabrizio De Benedetti, Fatma Dedeoglu, Erkan Demirkaya, Joost Frenkel, Raphaela
Goldbach-Mansky, Ahmet Gul, Veronique Hentgen, Hal Hoffman, Tilmann Kallinich, Isabelle Kone-Paut,
Jasmin Kuemmerle-Deschner, Helen J Lachmann, Ronald M Laxer, Avi Livneh, Laura Obici, Seza Ozen,
Dorota Rowczenio, Ricardo Russo, Yael Shinar, Anna Simon, Nataša Toplak, Isabelle Touitou, Yosef Uziel,
Marielle van Gijn, Dirk Foell, Claudia Garassino, Dan Kastner, Alberto Martini, Maria Pia Sormani, and
Nicolino Ruperto

Autoinflammatory disorders

Classification criteria for autoinflammatory
recurrent fevers
Marco Gattorno,  1 Michael Hofer,2,3 Silvia Federici,4 Federica Vanoni,5
Francesca Bovis,6 Ivona Aksentijevich,7 Jordi Anton,8 Juan Ignacio Arostegui,9
Karyl Barron,10 Eldad Ben-Cherit,11 Paul A Brogan,12 Luca Cantarini,13
Isabella Ceccherini,14 Fabrizio De Benedetti,15 Fatma Dedeoglu,16 Erkan Demirkaya,17
Joost Frenkel,18 Raphaela Goldbach-Mansky,19 Ahmet Gul,20 Veronique Hentgen,21
Hal Hoffman,22 Tilmann Kallinich,23 Isabelle Kone-Paut,24
Jasmin Kuemmerle-Deschner,25 Helen J Lachmann,26 Ronald M Laxer,27 Avi Livneh,28
Laura Obici,29 Seza Ozen,30 Dorota Rowczenio,26 Ricardo Russo,31 Yael Shinar,32
Anna Simon,33 Nataša Toplak,34 Isabelle Touitou,35 Yosef Uziel,36,37 Marielle van Gijn,38
Dirk Foell,39 Claudia Garassino,40 Dan Kastner,10 Alberto Martini,40
Maria Pia Sormani,6,41 Nicolino Ruperto42
Handling editor Josef S
Smolen
►► Additional material is
published online only. To view
please visit the journal online
(http://d x.doi.o rg/10.1136/
annrheumdis-2019-215048).

For numbered affiliations see
end of article.
Correspondence to
Dr Marco Gattorno, UOSD
Centro Malattie
Autoinfiammatorie e
Immunodeficienze, IRCCS
Istituto Giannina Gaslini, Genoa
16147, Italy;
m
 arcogattorno@gaslini.org
MG and MH contributed
equally.
Received 9 January 2019
Revised 30 March 2019
Accepted 1 April 2019

© Author(s) (or their
employer(s)) 2019. No
commercial re-use. See rights
and permissions. Published
by BMJ.
To cite: Gattorno M,
Hofer M, Federici S, et al.
Ann Rheum Dis Epub ahead
of print: [please include Day
Month Year]. doi:10.1136/
annrheumdis-2019-215048

Abstract
Background Different diagnostic and classification
criteria are available for hereditary recurrent fevers (HRF)—
familial Mediterranean fever (FMF), tumour necrosis factor
receptor-associated periodic fever syndrome (TRAPS),
mevalonate kinase deficiency (MKD) and cryopyrinassociated periodic syndromes (CAPS)—and for the
non-hereditary, periodic fever, aphthosis, pharyngitis and
adenitis (PFAPA). We aimed to develop and validate new
evidence-based classification criteria for HRF/PFAPA.
Methods Step 1: selection of clinical, laboratory and
genetic candidate variables; step 2: classification of 360
random patients from the Eurofever Registry by a panel
of 25 clinicians and 8 geneticists blinded to patients’
diagnosis (consensus ≥80%); step 3: statistical analysis for
the selection of the best candidate classification criteria;
step 4: nominal group technique consensus conference
with 33 panellists for the discussion and selection of the
final classification criteria; step 5: cross-sectional validation
of the novel criteria.
Results The panellists achieved consensus to classify
281 of 360 (78%) patients (32 CAPS, 36 FMF, 56 MKD,
37 PFAPA, 39 TRAPS, 81 undefined recurrent fever).
Consensus was reached for two sets of criteria for each
HRF, one including genetic and clinical variables, the other
with clinical variables only, plus new criteria for PFAPA.
The four HRF criteria demonstrated sensitivity of 0.94–1
and specificity of 0.95–1; for PFAPA, criteria sensitivity and
specificity were 0.97 and 0.93, respectively. Validation of
these criteria in an independent data set of 1018 patients
shows a high accuracy (from 0.81 to 0.98).
Conclusion Eurofever proposes a novel set of validated
classification criteria for HRF and PFAPA with high
sensitivity and specificity.

Introduction

In the last 20 years the discovery of the inflammasome and the related genes of the now called
systemic autoinflammatory diseases (SAIDs) has
led to a completely new line of research. SAIDs

Key messages
What is already known about this subject?

►► Hereditary recurrent fever (HRF) syndromes are

genetic disorders secondary to mutations in
genes involved in the innate immune response.
►► A number of classification or diagnostic criteria
have been developed in the past.
►► Overall, these criteria lack accuracy and do not
consider the results of genetic analyses, now
an essential tool for the accurate diagnosis and
classification of HRF.
What does this study add?

►► We developed and validate new evidence-based

classification criteria for HRF and periodic fever,
aphthosis, pharyngitis and adenitis, combining
international expert consensus, statistical
evaluation of real patients from a large data set
of patients in the Eurofever Registry.
►► The new classification criteria combine for the
first time clinical manifestations with genotype.
How might this impact on clinical practice or
future developments?
►► The use of these classification criteria is
recommended for inclusion of patients in
translational and clinical studies, but they
cannot be used as diagnostic criteria.

are caused by exaggerated activation of the innate
immune system, in the absence of high-titre autoantibodies or antigen-specific T-cells.1 1 Recurrent
(or periodic) fevers are characterised by inflammatory flares separated by intervals of general overall
well-being. Some conditions are caused by a genetic
defect and are collectively referred to as hereditary
recurrent fever (HRF). Familial Mediterranean
fever (FMF) is caused by mutations of MEFV2 3;
mevalonate kinase deficiency (MKD), by mutations

Gattorno M, et al. Ann Rheum Dis 2019;0:1–8. doi:10.1136/annrheumdis-2019-215048

   1

Ann Rheum Dis: first published as 10.1136/annrheumdis-2019-215048 on 24 April 2019. Downloaded from http://ard.bmj.com/ on December 9, 2019 at Univ Of West Ontario
GSTR101749364 Serials Acquisitions Unit. Protected by copyright.

Clinical science

Autoinflammatory disorders

Methods

A multistep process using consensus formation techniques
(Delphi and nominal group technique (NGT)) and statistical
evaluations on real patients was used to develop and test the classification criteria17 (online supplementary figure 1 and supplementary material), based on a methodological framework used
successfully in previous studies in rheumatology.20–25

Step 1: selection of clinical, laboratory and genetic candidate
variables

A panel of 162 international adult and paediatric experienced
clinicians completed successive Delphi questionnaires in order to
propose and then select and rank the variables (clinical manifestations, genetic analyses, laboratory examinations) from 1 (less
important) to 10 (most important), for classification of each
HRF26 and PFAPA.27

Step 2: classification of patients from the Eurofever Registry

After selection (online supplementary figure 2), a random sample
of 360 patients, 60 patients for each disease (FMF, TRAPS,
MKD, CAPS, PFAPA and undefined recurrent fevers (uRF)) were
selected from the Eurofever Registry.28 The inclusion criteria for
the enrolment in the registry have been previously described28
(see online supplementary material).
Twenty-five international experienced clinicians/researchers
and eight geneticists (total of 33 panellists) in the field of SAID
blinded on patients’ original diagnosis were invited to participate in a multiround, secured web process to classify each of
the 360 patients into one of six mutually exclusive diagnoses.29
Clinicians and geneticists worked separately in the first steps
(clinicians blinded to genetic results and geneticists blinded to
2

clinical data) and then together to reach consensus ≥80% on all
classifiable patients.

Step 3: statistical analysis for the selection of the best
candidate classification criteria

The statistical analysis plan (full details in the online supplementary material) foresaw the following steps:
►► Evaluation through a univariate logistic regression of the
relationship between each individual top variable identified in step 1 and each disease as derived from the panel’s
classification.
►► Computer generation of more than 30 000 new candidate
sets of classification criteria through linear combinations of
genetic and clinical variables with improper linear modelling. Additionally, 11 sets of criteria were derived from the
literature9–16 or proposed by members of the panel based on
their expertise.
►► Identification of the top-performing criteria through ranking
according to the Akaike information criterion (AIC), with
best model having the lowest AIC.

Step 4: NGT Consensus Conference for the selection of the
final classification criteria

The Consensus Conference was held in Genoa, Italy, on 18–21
March 2017. Clinicians and geneticists, who participated in the
step 2 web consensus classification exercise, attended a meeting.
The overall goal of the meeting was to decide on the final set of
criteria, using a combination of statistical and consensus (≥80%)
formation techniques with the consensus panel classification as
reference standard.

Step 5: cross-sectional validation of the final classification
criteria

The performance of the final set of classification criteria to
discriminate patients with the different HRF and PFAPA was
tested, using the original treating physician patients’ diagnosis
as reference standard for the cross-sectional validation, postconsensus, in a separate set of 1018 patients selected after random
computer generation from the Eurofever Registry, which
contains all variables included in the final set of classification
criteria.

Results

The demographic, clinical, genetic and laboratory features of the
360 patients randomly selected from the Eurofever Registry are
provided in table 1 and online supplementary table 1.
A total of 100 different genotypes were reported in the 360
patients included in the classification process as reported in
online supplementary table 2.
Nine patients with CAPS and two with TRAPS had no mutations detected using Sanger sequencing; thus, at the time of
enrolment, somatic mosaicism could not be formally excluded in
them. Low penetrant or incidental (non-confirmatory) genetic
findings were also reported in 7 patients with PFAPA and 14
with uRF (online supplementary table 3).

Classification of patients from the Eurofever Registry

In the first two rounds, evaluation of clinical data by clinicians
(blinded to genetic results) resulted in consensus of ≥80% for
a total of 216 of 360 (60%) patients (figure 1); consensus was
reached in 51 patients with MKD, 43 with TRAPS, 29 with FMF,
29 with CAPS, 26 with PFAPA and 38 with uRF. Similarly evaluation of demographic and genetic data by geneticists (blinded
Gattorno M, et al. Ann Rheum Dis 2019;0:1–8. doi:10.1136/annrheumdis-2019-215048
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of the mevalonate kinase gene (MVK)4 5; tumour necrosis factor
(TNF) receptor-associated periodic fever syndrome (TRAPS), by
mutations of type I TNF receptor (TNFSRF1A)6; and cryopyrin-associated periodic syndromes (CAPS), by mutations of
NLRP3.7 8 More common forms of recurrent fever syndromes
include periodic fever, aphthosis, pharyngitis and adenitis
(PFAPA) syndrome, which is a multifactorial disorder.9 So far,
several clinical diagnostic and classification criteria have been
proposed for HRF10–15 and PFAPA.9 16 Overall, these criteria lack
accuracy and do not consider the results of genetic analyses, now
an essential tool for the accurate diagnosis and classification of
HRF.
This distinction between classification and diagnostic criteria
is not always clear in clinical practice, and the two terms are
often (wrongly) used interchangeably.17 Classification criteria
facilitate accurate identification of diseases for clinical or epidemiological studies, in this context reliably differentiating one
autoinflammatory disease from another, but are not designed
to diagnose that autoinflammatory disease; hence, classification
criteria make the assumption that important disease mimics (eg,
chronic infection or malignancy) have already been excluded.
In contrast, diagnostic criteria are designed to positively rule
in a specific diagnosis in an individual patient, while excluding
all conditions with different overlapping disease manifestations based on derivation and validation in cohorts that include
important disease mimics. As such, classification criteria cannot
be used as diagnostic criteria.18 19 The purpose of this study was
to develop and validate new evidence-based classification criteria
for HRF and PFAPA, combining international expert consensus
and statistical evaluation of real patients from a large data set of
patients in the Eurofever Registry.

Autoinflammatory disorders
Demographic features of the 360 patients included in the study
FMF
n=60

CAPS
n=60

MKD
n=60

TRAPS
n=60

PFAPA
n=60

uRF
n=60

Male

30 (50%)

32 (53%)

26 (43%)

35 (58%)

28 (47%)

28 (47%)

Paediatric/Adults

54/6

33/27

45/15

29/31

59/1

39/21

Age, years, median (range)

10.5 (7.0–15.5)

16.0 (8.9–31.6)

16.2 (9.1–23.0)

21.9 (10.5–41.1)

6.6 (3.8–9.5)

13.5 (8.2–26.4)

Age at disease onset, median (range)

3.4 (1.2–6.4)

3.0 (0.5–11.2)

0.4 (0.2–0.9)

3.4 (0.8–10.6)

1.5 (0.7–3.0)

5.9 (2.0–19.1)

Disease duration, median (range)

5.6 (2.7–10.2)

9.0 (4.6–19.1)

14.2 (7.9–20.8)

13.3 (6.8–23.2)

3.9 (2.3–6.8)

4.8 (3.0–8.2)

Episode duration, median (range)

3.0 (2.0–4.0)

2.0 (0.8–5.0)

5.0 (4.0–7.0)

8.0 (5.0–18.0)

4.0 (3.0–5.0)

Number episodes/year, median (range)

12.0 (10.0–20.0)

12.0 (6.0–25.0)

12.0 (10.0–16.0)

6.0 (4.0–12.0)

12.0 (12.0–18.0)

4.0 (3.0–7.0)
12.0 (5.0–13.0)

CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; PFAPA, periodic fever, aphthosis, pharyngitis and adenitis;
TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome; uRF, undefined recurrent fevers.

to clinical data) in two separate rounds reached consensus on
319 of 360 (89%) with 278 (77%) patients with 80% consensus
after the first round. At the end of the two initial rounds, 128
(36%) patients were concordant between the independent evaluation of both the clinicians and the geneticists. At the end of
the fourth round, consensus was achieved in 281 of 360 (78%)
as follows: 56 (95%) MKD, 39 (76%) TRAPS, 37 (70%) PFAPA,
36 (71%) FMF, 32 (63%) CAPS and 81 (85%) uRF (figure 1,
online supplementary table 4). K (concordance coefficient)
agreement between the panel reference standard classification
and the original patient diagnosis by the treating physician was
0.99 for MKD, 0.87 for TRAPS, 0.86 for CAPS, 0.84 for FMF
and 0.68 for PFAPA.

Statistical analysis for the selection of the best classification
criteria

The top variables arising from step 1 (see the Methods section)
were included in a univariate logistic regression analysis using
the 281 patients for which consensus was achieved by the panel
as outcome. Clinical variables positively and negatively associated with each disease are reported in online supplementary
table 5 with the related OR and 95% CI. The strategy for the
classification of the genotypes is described in online supplementary table 6.
A total of 198 over >30 000 possible new sets of classification
criteria (available on request; 50 for CAPS, 45 for FMF, 44 for
TRAPS, 32 for MKD and 22 for PFAPA) were retained, based on

Figure 1 Flow chart of the consensus nominal group technique for classification of patients from the Eurofever Registry. CAPS, cryopyrin-associated
periodic syndromes; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; PFAPA, periodic fever, aphthosis, pharyngitis and adenitis;
pts, patients; TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome.
Gattorno M, et al. Ann Rheum Dis 2019;0:1–8. doi:10.1136/annrheumdis-2019-215048
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Table 1

Autoinflammatory disorders
New Eurofever/PRINTO classification criteria for hereditary recurrent fevers and their performance in the 281 patients with consensus
FMF

TRAPS

MKD

Presence of a confirmatory NLRP3
genotype* and at least one among the
following:
►► Urticarial rash.
►► Red eye (conjunctivitis, episcleritis,
uveitis).
►► Neurosensorial hearing loss.
OR
Presence of not confirmatory NLRP3
genotype† and at least two among the
following:
►► Urticarial rash.
►► Red eye (conjunctivitis, episcleritis,
uveitis).
►► Neurosensorial hearing loss.

Presence of confirmatory MEFV
genotype* and at least one among the
following:
►► Duration of episodes 1–3 days.
►► Arthritis.
►► Chest pain.
►► Abdominal pain.
OR
Presence of not confirmatory MEFV
genotype‡ and at least two among the
following:
►► Duration of episodes 1–3 days.
►► Arthritis.
►► Chest pain.
►► Abdominal pain.

Presence of confirmatory TNFRSF1A genotype*
and at least one among the following:
►► Duration of episodes ≥7 days.
►► Myalgia.
►► Migratory rash.
►► Periorbital oedema.
►► Relatives affected.
OR
Presence of a not confirmatory TNFRSF1A
genotype† and at least two among the
following:
►► Duration of episodes ≥7 days.
►► Myalgia.
►► Migratory rash.
►► Periorbital oedema.
►► Relatives affected.

Presence of a confirmatory MVK
genotype* and at least one among the
following:
►► Gastrointestinal symptoms.
►► Cervical lymphadenitis.
►► Aphthous stomatitis.

Sensitivity: 1

Sensitivity: 0.94

Sensitivity: 0.95

Sensitivity: 0.98

Specificity: 1

Specificity: 0.95

Specificity: 0.99

Specificity: 1

Accuracy: 1

Accuracy: 0.98

Accuracy: 0.99

Accuracy: 1

A patient with (1) evidence of elevation of acute phase reactants (ESR or CRP or SAA) in correspondence to the clinical flares and (2) careful consideration of possible
confounding diseases (neoplasms, infections, autoimmune conditions, other inborn errors of immunity) and a reasonable period of recurrent disease activity (at least 6 months) is
classified as having hereditary recurrent fever if the criteria are met.
*Pathogenic or likely pathogenic variants (heterozygous in AD diseases, homozygous or in trans (or biallelic) compound heterozygous in AR diseases).
†Variant of uncertain significance (VUS). Benign and likely benign variants should be excluded.
‡In trans compound heterozygous for one pathogenic MEFV variants and one VUS, or biallelic VUS, or heterozygous for one pathogenic MEFV variant. See online supplementary
table 7 for glossary.
AD, autosomal dominant; AR, autosomal recessive; CAPS, cryopyrin-associated periodic syndromes; CRP, C-reactive protein; ESR, erythocytes sedimentation rate; FMF, familial
Mediterranean fever; MKD, mevalonate kinase deficiency; MVK, mevalonate kinase; PRINTO, pediatric rheumatology international trial organization; SAA, serum amyloid A;
TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome.

their AIC, for further evaluation at the Consensus Conference,
together with 11 criteria from the literature (online supplementary figure 4).

NGT Consensus Conference for the selection of the final
classification criteria

The performances of all the criteria chosen by the consensus
in the 281 patients who reached a consensus are reported in
tables 2 and 3 (see also glossary in online supplementary table 7).

The first disease discussed was FMF. After multiple voting
sessions, all three tables of experts, which worked independently
from each other, showed a complete convergent validity selecting
the same top definition number 38 (online supplementary figure
4, session A), including genetic and clinical variables with a positive association (table 2). After general discussion, a second set
of criteria based solely on clinical criteria was selected to be used
as a possible tool for the indication for molecular analysis or as
classification criteria in case genetic testing is not locally available

Table 3 Eurofever/PRINTO clinical classification criteria for PFAPA and hereditary recurrent fevers and their performance in the 281 for whom
consensus was achieved
PFAPA

CAPS

FMF

TRAPS

MKD

At least seven out of eight:
Presence
►► Pharyngotonsillitis.
►► Duration of episodes, 3–6
days.
►► Cervical lymphadenitis.
►► Periodicity.
Absence
►► Diarrhoea.
►► Chest pain.
►► Skin rash.
►► Arthritis.

Presence of at least two of five*:
►► Urticarial rash.
►► Cold/Stress-triggered
episodes.
►► Sensorineural hearing loss.
►► Chronic aseptic meningitis.
►► Skeletal abnormalities
(epiphysial overgrowth/frontal
bossing).

At least six out of nine:
Presence
►► Eastern Mediterranean
ethnicity.
►► Duration of episodes, 1–3
days.
►► Chest pain.
►► Abdominal pain.
►► Arthritis.
Absence
►► Aphthous stomatitis.
►► Urticarial rash.
►► Maculopapular rash.
►► Painful lymph nodes.

Score ≥5 points:
Presence
►► Fever ≥7 days (2 points).
►► Fever 5–6 days (1 point).
►► Migratory rash (1 point).
►► Periorbital oedema (1 point).
►► Myalgia (1 point).
►► Positive family history (1
point).
Absence
►► Aphthous stomatitis (1 point).
►► Pharyngotonsillitis (1 point).

Presence of at least three of six:
►► Age at onset <1 years.
►► Gastrointestinal symptoms.
►► Painful lymph nodes.
►► Aphthous stomatitis.
►► Triggers.
►► Maculopapular rash.

Sensitivity: 0.97

Sensitivity: 0.80

Sensitivity: 0.91

Sensitivity: 0.87

Sensitivity: 0.91

Specificity: 0.93

Specificity: 0.91

Specificity: 0.92

Specificity: 0.92

Specificity: 0.82

Accuracy: 0.99

Accuracy: 0.85

Accuracy: 0.97

Accuracy: 0.96

Accuracy: 0.92

*Modified by Kuemmerle-Deschner et al.14 See online supplementary table 6 for glossary. See table 2 for prerequisite criteria.
CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; PFAPA, periodic fever, aphthosis, pharyngitis and adenitis;
PRINTO, pediatric rheumatology international trial organization; TRAPS, tumour necrosis factor receptor-associated periodic fever syndrome.
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Table 2
CAPS

Autoinflammatory disorders

Cross-validation of the final classification criteria
The ability of the new classification criteria to discriminate
among the different recurrent fevers and uFR was further
tested in the validation data set of 1018 patients extracted
from the Eurofever Registry (online supplementary table 9)
using as reference standard for each patient the diagnosis
given by the treating physician. In the last column of table 4,
the genotype (score 0=negative/not done; score 1=not confirmatory; score 2=confirmatory) of patients not identified by
the clinical criteria for HRF is reported. Notably, almost all
the patients not classified by the clinical and genetic criteria
displayed a negative or not confirmatory genotype (table 4).
The performance of the new classification criteria (either
clinical and genetic or clinical only) was generally superior
(accuracy ranging from 0.81 to 0.98; table 4) to those already
available in the literature (accuracy 0.56–0.94) (online supplementary table 10).
Gattorno M, et al. Ann Rheum Dis 2019;0:1–8. doi:10.1136/annrheumdis-2019-215048

Discussion
The present study provides new evidence-based classification
criteria for the four ‘classical’ HRF (FMF, MKD, TRAPS, CAPS)
and PFAPA, incorporating combined consensus expertise of clinicians and geneticists with statistical analyses in real patients from
the Eurofever Registry. At variance with past work15 these new
classification criteria combine genetic and clinical variables to
overcome the paradox of the absence of a role of the molecular
analysis for the proper identification of patients affected by these
(mainly) genetic conditions. As defined by the American College
of Rheumatology, the proposed classification criteria have
selected clinical and genetic findings able to identify the defined
diseases and separate from other confounding autoinflammatory
conditions.18 19 Although these criteria may at times be helpful in
clinical practice, they are explicitly not meant to be employed as
diagnostic criteria. The advent of the so-called next-generation
sequencing era resulted on one side to an increased availability
of the molecular analysis at reduced costs but might often lead
to difficulties in the proper interpretation of this large set of
bioinformatic data. In fact, besides the identification of clearly
pathogenic variants, in many circumstances (ie, low penetrance
variants or variants of unknown significance, monoallelic variants in autosomal recessive diseases, presence of variants in
more than one gene) the genetic results are not unequivocal and
should be placed in the context of a pertinent clinical setting. In
these latter cases, the classification of the patient is usually problematic, as clearly shown in the process of patients’ validation
in this study. For these reasons, the panel decided to introduce
a distinction between a confirmatory (namely, surely or likely
pathogenic variants) and not confirmatory (variants of unknown
significance) genetic test. For the daily use of the new criteria,
a parallel consensus classification effort by the genetic subcommittee of the INSAID project has established the pathogenicity
of each currently known variant associated to HRF.30 A differential approach for the interpretation of the biallelic variants was
chosen for the two autosomal recessive diseases, namely MKD
and FMF. MKD is caused by loss-of-function mutations in the
MVK gene. The panel excluded the possibility of classifying a
patient as an MKD in the absence of biallelic mutations of the
MVK gene. Conversely, recent evidence has clarified that FMF
is secondary to gain-of-function mutations of the MEFV gene,
with a clear dose effect,31 32 and therefore FMF could be classified with identification of either one or two pathogenic variants in exon 10 of MEFV in the presence of a consistent clinical
phenotype. The same possibility was also considered for the
two autosomal dominant diseases, CAPS and TRAPS, in the
absence of confirmatory phenotype. In patients carrying variants of unknown pathogenic significance (such as R92Q and
P46L for TNFRSF1A, or V198M for NLRP3),33–36 only the presence of some very specific clinical variables would support the
proper disease classification. In parallel with the elaboration of
the definitive criteria that include genetic/clinical variables, the
panel agreed on additional clinical criteria that should be used
to (1) identify patients with recurrent fevers that would need to
undergo genetic testing for molecular confirmation; (2) search
for possible somatic mosaicism using NG in patients with a clear
phenotype, but negative Sanger sequencing results; and (3) classify patients (eg, for epidemiological studies) even in those countries where routine genetic testing is not possible. For PFAPA, the
contemporary evaluation of either positive (presence) and negative (absence) clinical variables yielded a much higher accuracy
when compared with the classical modified Marshall’s criteria.16
Following the consensus meeting, the new sets of criteria were
5
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(online supplementary figure 4, session B). To this aim, definition number 12, including clinical variables with both positive
and negative association with the disease, was chosen (table 3).
The same approach was followed for the other HRFs (CAPS,
TRAPS, MKD), leading to the selection of criteria with genetic
and clinical variables (number 32 for CAPS, number 46 for
TRAPS, number 37 for MKD) (table 2, online supplementary
figures 6-8). As per the process to establish FMF criteria, a
set of purely clinical criteria (ie, without genetic results) was
also selected for each HRF, namely definitions number 20 and
number 1 for MKD and TRAPS, respectively (table 3). For
CAPS classification, the experts reached consensus on a modified version of recently published criteria.14 The performance
of the original Kummerle criteria (using two out of six criteria)
in the context of the present study population displayed
a good sensitivity (0.91), but a low specificity (0.80).14
In contrast, when the variable ‘musculoskeletal pain’ was
excluded, a higher specificity (0.94, with a sensitivity of 0.80)
was achieved, if two out of five criteria are present (table 3).
The most severe form of CAPS, chonic infantile neurological
cutaneous articular (CINCA)/neonatal onset multisystemic
inflammatory disorder (NOMID), displays a chronic rather
than a recurrent disease course. Patients with CINCA were not
included in the validation process described above. However,
when the new genetic and clinical CAPS criteria were tested in
a separate set of 70 patients with CAPS with chronic disease
course enrolled in the Eurofever Registry, the sensitivity was
100% for the genetic and clinical criteria and 80% for the
clinical criteria (not shown).
Clinical classification criteria for PFAPA were discussed
between the 25 clinical panellists distributed in two tables (no
geneticists). After discussion (online supplementary figure 8),
definition number 13 (clinical variables with both positive and
negative association) was chosen (table 3). During the Consensus
Conference, the panel agreed on a few suggested mandatory
criteria that should be fulfilled in all the patients before the application of the new classification criteria (table 3) with a consensus
of 100% for point 1 and 96% for point 2.
Globally, convergent validity among the three tables of experts
was obtained for the genetic and clinical definitions of FMF and
CAPS, whereas for all the other definitions a partial convergent
validity (agreement in two out of three tables) was reached, with
the need for a final plenary voting session (online supplementary
figures 4-8 and online supplementary table 8).
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FP: 24/1001

TN: 752/1001

TP: 149/1001

FN: 42/940

FP: 33/940

TN: 813/940

TP: 52/940

FN: 26/1000

FP: 1/1000

TN: 900/1000

TP: 73/1000

FN: 14/818

FP: 144/818

TN: 617/818

TP: 43/818

FN: 16/1005

FP: 0/1005

TN: 944/1005

TP: 45/1005

FN: 50/940

FP: 39/940

61.4

30.4

2526.9

13.2

5209.1

0.66

0.55

0.74

0.75

0.74

0.97

0.96

1

0.81

1

0.9

0.92

0.97

0.81

0.98

0.82

0.76

0.87

0.78

0.87

0.89

3/50 pts, score 0 (6,12%)

11/42 pts, score 2 (28.95 %)

27/42 pts, score 1 (71.05%)

20/26 pts, score 1 (76.92%)

6/26 pts, score 0 (23.08%)

11/14 pts, score 2 (84.62%)

2/14 pts, score 1 (15.38%)

14/16 pts, score 1 (87.5%)

2/16 pts, score 0 (12.5%)

20/50 pts, score 2 (40,82 %)

0.91

TN: 568/940

0.94

26/50 pts, score 1 (53,06%)

0.85

12/39 pts, score 0 (30.77%)

TP: 283/940

FN: 39/1010
82.4

0.94
1/39 pts, score 2 (2.56%)

0.96
26/39 pts, score 1 (66.67%)

1

FP: 3/1010

0.89

3/25 pts, score 0 (13.04%)

TN: 664/1010

TP: 304/1010

FN: 25/925
1725.3

0.88
12/25 pts, score 2 (52.17 %)

0.96

FP: 12/925

0.99
8/25 pts, score 1 (34.78%)

0.77

27/38 pts, score 0 (71.05%)

TN: 806/925

TP: 82/925

FN: 38/1013
220.3

0.86

Score 2: 11/11

Score 1: 8/27

Score 2: 10/11

Score 1: 0/2

Score 2: 19/20

Score 1: 8/26

Score 0: 0/3

Score 2: 11/12

Score 1: 1/8

Score 0: 0/3

For explanation of the scores 0–1–2, see online supplementary table 6.
CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; FN, false negative; FP, false positive; MKD, mevalonate kinase deficiency; PFAPA, periodic fever, aphthosis, pharyngitis and adenitis; pts, patients.TN, true negative; TP, true positive; TRAPS, tumour necrosis factor
receptor-associated periodic fever syndrome;

PFAPA clinical

TRAPS clinical

TRAPS clinical + genetics

MKD clinical

MKD clinical + genetics

FMF clinical

FMF clinical + genetics

CAPS clinical

0.96
1/38 pts, score 2 (2.63%)

1
10/38 pts, score 1 (26.32%)

0.72

FP: 0/1013

4490

TN: 877/1013

TP: 98/1013

Performance of the new classification criteria to discriminate different recurrent fevers in the validation data set of patients extracted from the Eurofever Registry (N=1018)
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Table 4
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further validated in a large group of additional patients from
the Eurofever Registry, showing a very high specificity when
compared with previous literature criteria. As noticed, most of
the diagnoses refuted by the new criteria had been in patients
with either non-confirmatory or negative genetic tests results.
It is therefore conceivable that the present new criteria will be
more stringent in the classification of patients, by excluding a
substantial proportion of patients carrying variants of unknown
origin. The classification criteria we propose are accurate for the
discrimination of one form of autoinflammation from another
in the context of the six conditions considered herein, but very
much have to be applied judiciously, after careful consideration
of confounding diseases, as highlighted in table 2. These classification criteria are therefore intended for use for clinical, epidemiological or translational studies, but not for routine diagnostic
purposes in individual patients.37 That said, the purely clinical
classification criteria might guide molecular testing approaches
for individual cases, although this point requires future validation. One possible limitation of the present study is the lack of
comparison groups including possible confounding conditions
(chronic infections, neoplasms, immune deficiencies, autoimmune disease and metabolic diseases) presenting sometimes with
a recurrent disease course. In daily practice confounding diseases
with a true recurrent disease course are rather infrequent
outside HRF and PFAPA, while the most challenging group of
confounding conditions are the large emerging group of patients
with uRF, many of whom may have a true monogenetic cause
other than the four genetic diseases considered herein. For these
reasons, the different HRFs have been used as controls for each
individual condition with PFAPA and uRF as genetically negative controls. The panel of experts unanimously decided that
the presence of elevation of acute phase reactants during disease
flares (recorded at least in one occasion) should be considered as
mandatory preliminary criterion for the use of the new classification criteria.14 Some other relevant pathognomonic laboratory
examinations, such as urinary mevalonic acid in MKD, were not
available in the Eurofever Registry, probably reflecting the fact
that it is not widely available for testing routinely. As such the
panel recommended the importance for the diagnostic workup, for example, with intracellular MVK enzyme activity and/
or urinary mevalonic acid in MKD,38 particularly for patients
with convincing phenotypes but non-confirmatory genotype
for MKD. Similarly, the response to some specific treatments
(such as colchicine in FMF or anti-interleukin (IL)-1 in CAPS)
or ethnic background (for FMF) could certainly be considered as
additional elements to be considered in daily practice, especially
for patients with non-confirmatory genotype, but are not good
discriminators of the different forms of autoinflammatory disease
considered herein. In conclusion, the present work allowed the
proposal of novel evidence-based classification criteria for HRF
and PFAPA with a high specificity. The use of these classification criteria is highly recommended for inclusion of patients in
translational and clinical studies, including clinical trials, and
should not be misused as diagnostic criteria.17 The possible identification of new genetic entities in the heterogeneous group of
undefined periodic fevers could require an update of the criteria
in the future.
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